- Home
- LUNG vs CLLS Comparison
LUNG vs CLLS Comparison
Compare LUNG & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUNG
- CLLS
- Stock Information
- Founded
- LUNG 1995
- CLLS 1999
- Country
- LUNG United States
- CLLS France
- Employees
- LUNG N/A
- CLLS N/A
- Industry
- LUNG Industrial Specialties
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- LUNG Health Care
- CLLS Health Care
- Exchange
- LUNG Nasdaq
- CLLS Nasdaq
- Market Cap
- LUNG 248.0M
- CLLS 240.2M
- IPO Year
- LUNG 2020
- CLLS 2007
- Fundamental
- Price
- LUNG $6.67
- CLLS $2.01
- Analyst Decision
- LUNG Strong Buy
- CLLS Buy
- Analyst Count
- LUNG 7
- CLLS 2
- Target Price
- LUNG $13.71
- CLLS $8.00
- AVG Volume (30 Days)
- LUNG 207.8K
- CLLS 22.3K
- Earning Date
- LUNG 10-28-2024
- CLLS 11-04-2024
- Dividend Yield
- LUNG N/A
- CLLS N/A
- EPS Growth
- LUNG N/A
- CLLS N/A
- EPS
- LUNG N/A
- CLLS N/A
- Revenue
- LUNG $76,583,000.00
- CLLS $19,635,000.00
- Revenue This Year
- LUNG $22.73
- CLLS $271.02
- Revenue Next Year
- LUNG $19.02
- CLLS $33.48
- P/E Ratio
- LUNG N/A
- CLLS N/A
- Revenue Growth
- LUNG 26.26
- CLLS N/A
- 52 Week Low
- LUNG $5.46
- CLLS $0.96
- 52 Week High
- LUNG $14.84
- CLLS $3.77
- Technical
- Relative Strength Index (RSI)
- LUNG 37.51
- CLLS 41.74
- Support Level
- LUNG $6.39
- CLLS $1.95
- Resistance Level
- LUNG $7.47
- CLLS $2.06
- Average True Range (ATR)
- LUNG 0.36
- CLLS 0.10
- MACD
- LUNG -0.20
- CLLS -0.01
- Stochastic Oscillator
- LUNG 12.93
- CLLS 33.33
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.